SecBot SecBot
8-K ·Filed Jul 7, 2026

VERA

Vera Therapeutics, Inc.
BULLISH
Impact 7/10
Horizonimmediate Processed4mo ago SEC0001193125-26-297211
Actionable Insight ▲ Bullish

Expect a strong positive stock reaction on the approval news. Monitor for commercial launch details, pricing, and any confirmatory trial requirements that could affect long-term label durability. Watch for potential partnership or manufacturing updates in the coming weeks.

DirectionBullish
Confidencehigh
Horizonimmediate

TRUTAKNA

▲ Bullish Named in this 8-K
Impact
Phase
Approved (Accelerated Approval)
Time to market
Already FDA-approved (July 7, 2026) — launched commercially; confirmatory full-approval data expected Q3 2026
Next catalyst
None dated

What to watchThe FDA approval is already priced in (modest +6.8% move on the day). The real binary catalysts ahead are the ORIGIN 3 eGFR confirmatory data (Q3 2026) and commercial launch execution metrics. Watch pricing/reimbursement decisions, early prescription uptake, and whether the confirmatory eGFR data supports full approval. The IgAN market is getting crowded (Tarpeyo, Filspari, Fabhalta, Vanrafia, Voyxact), so differentiation on convenience (at-home autoinjector) and upstream mechanism (dual BAFF/APRIL) will determine commercial success.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$42.96
T+0 close · Jul 7, 2026 · via day close
Latest settled
−24.84%
T+60 · $32.29
Vs SPY
−26.83%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 7 $42.96entry
  2. T+1 · 4mo ago −1.23%α −0.92% · $42.43
  3. T+5 · 4mo ago +0.40%α −0.16% · $43.13
  4. T+20 · 4mo ago −24.98%α −26.31% · $32.23
  5. T+60 · 7w ago −24.84%α −26.83% · $32.29
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vera Therapeutics announced FDA accelerated approval for TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. This is a transformative regulatory milestone that unlocks a commercial market for the company's lead drug candidate.

Key Facts

  • FDA granted accelerated approval for TRUTAKNA (atacicept-vymj) on July 7, 2026.
  • Indication: reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression.
  • No financial terms, pricing, or revenue guidance were disclosed in the filing.

Financial Impact

Significant revenue potential from a first-in-class treatment for IgAN; no specific dollar amounts provided in the filing.

revenue

Risk Factors

  • Accelerated approval requires confirmatory trials; failure to confirm clinical benefit could lead to withdrawal.
  • Competition from other IgAN therapies (e.g., sparsentan, budesonide) may limit market share.
  • Commercial execution and manufacturing scale-up risks for a newly approved biologic.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (VERA), Batch item 10001193125-26-297211
Document: 0001193125-26-297211-index-headers.html0001193125-26-297211
Document: 0001193125-26-297211-index.html0001193125-26-297211
Document: 0001193125-26-297211.txt0001193125-26-297211
8-K Filing (VERA), Batch item 50001193125-26-297211
Document: 0001193125-26-297211-index-headers.html0001193125-26-297211
Document: 0001193125-26-297211-index.html0001193125-26-297211
Document: 0001193125-26-297211.txt0001193125-26-297211

Track record

25 reports on VERA

Performance horizon

12 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +36.47% at T+20 after the Jun 2, 2026 report. 13 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $27.55 Now $26.97 −2.11% settles Nov 23
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
  4. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $30.03 Now $26.97 −10.19% settles Nov 17
  5. Nov 5, 202611d ago 8-K Bullish 6/10 No price data
  6. Nov 5, 202611d ago Press Release Bullish 6/10 Entry $29.79 to $28.10 Now $26.97 −9.45% ▼ −5.66% −8.25% vs SPY
  7. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.97 to $30.48 Now $26.97 −15.64% ▼ −4.66% −3.75% vs SPY
  8. Oct 22, 202625d ago Press Release Bullish 8/10 Entry $29.05 to $30.53 Now $26.97 −7.16% ▲ +5.09% +4.39% vs SPY
  9. Sep 15, 20268w ago 8-K Bullish 8/10 Entry $33.67 to $34.00 Now $26.97 −19.90% ▲ +0.98% +0.16% vs SPY
  10. Aug 10, 202614w ago 8-K Neutral 5/10 No price data
Showing 10 of 25

US Market Status

Market Closed · Opens Wed (9h 51m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 7, 2026